| Literature DB >> 35852994 |
Ferdinand D Guzman1, Yuta Iwamoto2, Nobuo Saito2,3,4, Eumelia P Salva1, Efren M Dimaano1, Akira Nishizono4, Motoi Suzuki2,5, Oladeji Oloko6, Koya Ariyoshi2,3, Chris Smith2,3,6, Christopher M Parry2,7, Rontgene M Solante1.
Abstract
Rabies remains a public health problem in the Philippines despite the widespread provision of rabies vaccines and rabies immunoglobulin (RIG) as post-exposure prophylaxis (PEP). Detailed descriptions of recent human rabies cases in the Philippines are scarce. This study aimed to describe the clinical, epidemiological, and spatial features of human rabies cases between January 1, 2006, and December 31, 2015. We conducted a retrospective hospital-based case record review of all patients admitted to one referral hospital in Manila who received a clinical diagnosis of rabies. During the 10-year study period there were 575 patients (average 57.5 cases per year, range 57 to 119) with a final diagnosis of rabies. Most patients were male (n = 404, 70.3%) and aged ≥ 20 years (n = 433, 75.3%). Patients mostly came from the National Capital Region (n = 160, 28.0%) and the adjacent Regions III (n = 197, 34.4%) and IV-A (n = 168, 29.4%). Case mapping and heatmaps showed that human rabies cases were continuously observed in similar areas throughout the study period. Most patients had hydrophobia (n = 444, 95.5%) and/or aerophobia (n = 432, 93.3%). The leading causative animals were dogs (n = 421, 96.3%) and cats (n = 16, 3.7%). Among 437 patients with animal exposure history, only 42 (9.6%) had been administered at least one rabies vaccine. Two patients (0.5%), young children bitten on their face, had received and a full course of rabies vaccine. Human rabies patients were continuously admitted to the hospital, with no notable decline over the study period. The geographical area in which human rabies cases commonly occurred also did not change. Few patients received PEP and there were two suspected cases of PEP failure. The retrospective design of this study was a limitation; thus, prospective studies are required.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35852994 PMCID: PMC9295989 DOI: 10.1371/journal.pntd.0010595
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Flow chart of the inclusion for each analysis in this study.
Fig 2Comparisons of human rabies cases in San Lazaro Hospital between 2006–2015 and 1987–2006.
(A) Annual numbers of admissions. (B) Annual numbers of patients according to sex. (C) Annual numbers of patients per age group of.
Fig 3Case locations.
Locations of San Lazaro Hospital, National Capital Region (gray), Manila City (black), Quezon City (dark gray), Region III (Shaded area), San Jose Delmonte City (light gray), Region IV-A (grid), and Antipolo City (light gray). Regional, provincial, city, and municipal boundary data and base maps were obtained from the United Nations Office for the Coordination of Human Affairs (OCHA). (https://data.humdata.org/dataset/philippines-administrative-levels-0-to-3).
Fig 4Geographical distributions of patient residential addresses among those admitted to San Lazaro Hospital with a final diagnosis of rabies between 2006 and 2015.
(A) Numbers of rabies cases in municipalities or cities. (B) Case mapping and heatmaps of rabies cases in Metro Manila, Region III, and Region IV-A. (C) Enlarged scale map focusing on cases and the heatmap in Metro Manila. (D) Heatmaps showing the case densities of human rabies cases during two observational periods (2006–2010 [transparent blue] and 2011–2015 [red]); each dot represents the residential address of a rabies case, with different colors representing the year of admission. Regional, provincial, city, and municipal boundary data and base maps were obtained from the United Nations Office for the Coordination of Human Affairs (OCHA). (https://data.humdata.org/dataset/philippines-administrative-levels-0-to-3).
Clinical symptoms, interventions, and hospitalization duration among 463 patients with available medical charts and comparison to those reported previously.
| Clinical symptoms | 2006–2011 n = 463 N (%: 95%CI) | 1987–2006 [ | |
|---|---|---|---|
| Prodromal symptoms | Bite site symptomsa | 82 (17.7: 14.3–21.5) | 91 (4.9) |
| Fever ≥37.0°C | 224 (48.4: 43.7–53.0) | 173 (9.4) | |
| Nausea/vomiting | 103 (22.3: 18.5–26.3) | 119 (6.5) | |
| Acute neurological symptoms | Restlessness | 306 (66.1: 61.6–70.4) | 169 (9.2) |
| Confusion/agitation | 176 (38.0: 33.6–42.6) | ||
| Behavioral change | 106 (22.9: 19.1–27.0) | ||
| Seizure | 6 (1.3: 0.5–2.8) | ||
| Paralysis | 2 (0.4: 0.1–1.6) | 71 (3.9) | |
| Autonomic dysfunction | Hydrophobia | 444 (95.9: 93.7–97.5) | 1839 (100) b |
| Aerophobia | 432 (93.3: 90.6–95.4) | 1756 (95.5) | |
| Difficulty breathing | 190 (41.0: 36.5–45.7) | ||
| Dyphagia | 119 (25.7: 21.8–29.9) | ||
| Hypersalivation | 116 (25.1:21.2–29.3) | 124 (6.7) | |
| Photophobia | 44 (9.5: 7.0–12.5) | 23 (1.3) | |
| Intervention | Diphenhydramine | 397 (85.8: 82.2–88.8) | |
| Haloperidol | 370 (79.9: 76.0–83.5) | ||
| Diazepam | 193 (41.7: 37.2–46.3) | ||
| IV fluid | 36 (7.8: 5.5–10.6) | ||
| Mechanical ventilator | 1 (0.2: 0.00–1.2) | ||
| Hospitalization duration (hours) | ≤24 hours | 324 (70.0: 65.6–74.1) | |
| 25–48 hours | 104 (22.5: 18.7–26.5) | ||
| 49–72 hours | 23 (5.0: 3.2–7.4) | ||
| 73–168 hours | 11 (2.4: 1.2–4.2) | ||
| Unknown/no record | 1 (0.2: 0.00–1.2) |
95%CI: 95% confidence interval. apain, itching, or numbness; IV: intravenous bclinical rabies was defined as the presence of hydrophobia in this study.
Characteristics of the casual animals, exposures, and post-exposure prophylaxis among 437 patients reporting animal exposures compared to a previous study.
| 2006–2011 n = 467 N (%: 95%CI) | 1987–2006 [ | ||
|---|---|---|---|
| Animal type | Dog | 421 (96.3: 94.1–97.9) | 1639 (97.1) |
| Cat | 16 (3.7: 2.1–5.9) | 49 (2.9) | |
| Pet or stray | Pet | 113 (25.9: 21.8–30.2) | 581 (35.5) |
| Stray | 78 (17.8: 14.3–21.8) | 1057 (64.5) | |
| Unknown/not recorded | 246 (56.3: 51.5–61.0) | ||
| Animal condition | Died | 88 (20.1: 16.5–24.2) | |
| Euthanasia | 100 (22.9: 19.0–27.1) | ||
| Unknown/not recorded | 249 (57.0: 52.2–61.7) | ||
| Exposure contact | Bite | 415 (95.0: 92.5–96.8) | 1814 (98.6) |
| Scratch | 10 (2.3: 1.1–4.2) | ||
| Lick | 7 (1.6: 0.6–3.3) | ||
| Othera | 5 (1.1: 0.4–2.6) | 21 (84) | |
| Bite exposure (n = 415) | Single | 310 (74.7: 70.2–78.8) | |
| Multiple | 13 (3.1: 1.7–5.3) | ||
| Unknown/not recorded | 92 (22.2: 18.3–26.5) | ||
| Body sites of bite exposure(s)b | Face, head, or neck | 21 (4.8: 3.0–7.3) | |
| Fingers | 44 (10.1: 7.4–13.3) | ||
| Upper extremities | 115 (26.3: 22.2–30.7) | ||
| Lower extremities | 151 (34.6: 30.1–39.2) | ||
| Incubation period (days) | ≤30 | 99 (22.7: 18.8–26.9) | 292 (16.0) |
| 30–90 | 184 (42.1: 37.4–46.9) | 498 (27.3) | |
| 91–365 | 81 (18.5: 15.0–22.5) | 785 (43.0) | |
| >365 | 41 (9.4: 6.8–12.5) | 251 (13.7) | |
| Unknown/no record | 33 (7.6: 5.3–10.4) | ||
| Rabies vaccine and RIG as post-exposure prophylaxis | No vaccine and No RIG | 395 (90.4: 87.2–93.0) | 1808 (98.3) |
| 1 dose, no RIG | 20 (4.6: 2.8–7.0) | ||
| 1 dose + RIG | 4 (0.9: 0.2–2.3) | 8 (0.4) | |
| 2 doses No RIG | 7 (1.6: 0.6–3.3) | 22 (1.1)c | |
| 2 doses + RIG | 1 (0.2: 0.00–1.3) | ||
| ≥3 doses, No RIG | 8 (1.8: 0.8–3.6) | ||
| ≥3 doses + RIG | 2 (0.5: 0.0–1.6) | 1 (0.05)e |
95%CI: 95% confidence interval. RIG, rabies immunoglobulin.
aMost other reported exposures were dog meat consumption or cooking raw animal meat
bmultiple choice
cthe doses of rabies vaccines were not clearly indicated
eRIG treatment was delayed for 2 days after animal exposure. The patient experienced multiple facial bites. RIG was administered intramuscularly.
Characteristics of patients with rabies who received >3 doses of post-exposure prophylaxis.
| Age (years) | Month and year of admission | Single or multiple bites | Exposure site | Vaccine doses | RIG | Doses administered according to schedule | Duration between bite and admission |
|---|---|---|---|---|---|---|---|
| 36 | Feb 2007 | − | − | 4 doses | − | − | 2 months |
| 64 | Jan 2010 | Single | Legs | 5 doses | − | − | 1 year |
| 48 | Jan 2012 | Single | Arms | 4 doses | N | − | 2 months |
| 3 | May 2012 | Single | Legs | 4 doses | − | − | 30 days |
| 20 | Sep 2013 | − | − | 4 doses | − | − | 6 months |
| 2a | Jan 2014 | Multiple | Face, head, arm | 4 doses | Y | Y | 30 days |
| 5a | Feb 2014 | Single | Face | 3 doses | Y | Y | 21 days |
| 25 | April 2015 | − | − | 4 doses | − | − | 60 days |
| 56 | Jun 2015 | Single | Face | 3 doses | N | N | 30 days |
| 14 | Dec 2015 | − | − | 4 doses | − | − | 30 days |
RIG: rabies immunoglobulin; −: no record or unknown; N: no; Y: yes.
apatients received the complete post-exposure prophylaxis regime (RIG + series of vaccinations).